Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 2, 2007, Pages 78-88

  Cefali, E A ^a   Simmons, P D ^a   Stanek, E J ^a   McGovern, M E ^a   Kissling, C J ^b   Adams, Marijke H ^c  

^a Kos Pharmaceuticals Inc   (United States)

^b MDS Inc   (Canada)

^c NONE   (United States)

Author keywords

Aspirin; Flushing; Formulation; Niacin; Prophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SKIN MANIFESTATION; SKIN PRURITUS; SKIN REDNESS; SKIN TINGLING; SORE THROAT; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; VISUAL ANALOG SCALE;

EID: 33847421500     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45078     Document Type: Article

References (12)

1. Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med. 2004; 62: 229-234.
2. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998; 82: 74U-81U.
3. Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharm Ther. 2006; 44: 633-640.
4. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother. 2004; 5: 1385-1398.
5. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol. 1998; 82: 24U-28U; discussion 39U-41U.
6. Morgan JM, Capuzzi DM, Guyton JR et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996; 1: 195-202.
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
8. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006; 60: 707-715.
9. Pieper JA. Understanding niacin formulations. Am J Manag Care. 2002; 8 (12 Suppl): S308-S314.
10. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000; 86 (Suppl): 35L-40L.
11. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005; 96: 53E-59E.
12. Tavintharan S, Kashyap ML. The benefits of niacin in atherosclerosis. Curr Atheroscler Rep. 2001; 3: 74-82